Maternal mortality related to pulmonary embolism in the United States, 2003-2020.

Centers for Disease Control and Prevention multiple causes of death epidemiology maternal mortality pregnancy pulmonary embolism venous thrombosis

Journal

American journal of obstetrics & gynecology MFM
ISSN: 2589-9333
Titre abrégé: Am J Obstet Gynecol MFM
Pays: United States
ID NLM: 101746609

Informations de publication

Date de publication:
01 2023
Historique:
received: 16 09 2022
accepted: 19 09 2022
pubmed: 27 9 2022
medline: 21 12 2022
entrez: 26 9 2022
Statut: ppublish

Résumé

Pulmonary embolism is a leading cause of maternal morbidity and mortality in Western countries. In the United States, pulmonary embolism-related mortality rates have plateaued in the general population after an initial decrease in the past 20 years. This study aimed to describe the changes in pulmonary embolism-related maternal mortality rates in the United States over the past 2 decades. In this epidemiologic study of public vital registration data (death certificates encompassing underlying and contributing causes of death) from the Centers for Disease Control and Prevention Multiple Cause of Death database (2003-2020), we identified all maternal deaths with a pulmonary embolism code listed in any position of the death certificates. We investigated the changes in annual crude pulmonary embolism-related maternal mortality rates for the years 2003 to 2020, considering the effect of the introduction of the pregnancy checkbox in death certificates on the pulmonary embolism-related maternal mortality rates. Overall, 735 pulmonary embolism-related maternal deaths out of 12,871 total maternal deaths (5.7%) were recorded between 2003 and 2020; the overall pulmonary embolism-related maternal mortality rate was 1.02 (95% confidence interval, 0.95-1.10) per 100,000 live births. The pulmonary embolism-related maternal mortality rate increased from 0.93 in 2003 to 1.96 in 2020; however, when accounting for the implementation of the pregnancy checkbox in the death certificates, the trends in pulmonary embolism-related maternal mortality were largely unchanged from 2003 to 2020. The crude pulmonary embolism-related maternal mortality rates differed across maternal age groups (overall 0.61, 1.09, and 3.83 maternal deaths per 100,000 live births for those aged ≤24, 25-39, and ≥40 years, respectively) and racial/ethnicity groups (2.89, 0.47, 0.77, and 0.63 maternal deaths per 100,000 live births for Black non-Hispanics, other non-Hispanics, White non-Hispanics, and Hispanics, respectively). Maternal mortality rates related to pulmonary embolism did not decrease during the period from 2003 to 2020, as opposed to mortality rates related to pulmonary embolism in the general population. More research is required to assess whether improvement in venous thromboembolism prevention and pulmonary embolism diagnosis and management strategies might reduce death owing to pulmonary embolism in this vulnerable population.

Sections du résumé

BACKGROUND
Pulmonary embolism is a leading cause of maternal morbidity and mortality in Western countries. In the United States, pulmonary embolism-related mortality rates have plateaued in the general population after an initial decrease in the past 20 years.
OBJECTIVE
This study aimed to describe the changes in pulmonary embolism-related maternal mortality rates in the United States over the past 2 decades.
STUDY DESIGN
In this epidemiologic study of public vital registration data (death certificates encompassing underlying and contributing causes of death) from the Centers for Disease Control and Prevention Multiple Cause of Death database (2003-2020), we identified all maternal deaths with a pulmonary embolism code listed in any position of the death certificates. We investigated the changes in annual crude pulmonary embolism-related maternal mortality rates for the years 2003 to 2020, considering the effect of the introduction of the pregnancy checkbox in death certificates on the pulmonary embolism-related maternal mortality rates.
RESULTS
Overall, 735 pulmonary embolism-related maternal deaths out of 12,871 total maternal deaths (5.7%) were recorded between 2003 and 2020; the overall pulmonary embolism-related maternal mortality rate was 1.02 (95% confidence interval, 0.95-1.10) per 100,000 live births. The pulmonary embolism-related maternal mortality rate increased from 0.93 in 2003 to 1.96 in 2020; however, when accounting for the implementation of the pregnancy checkbox in the death certificates, the trends in pulmonary embolism-related maternal mortality were largely unchanged from 2003 to 2020. The crude pulmonary embolism-related maternal mortality rates differed across maternal age groups (overall 0.61, 1.09, and 3.83 maternal deaths per 100,000 live births for those aged ≤24, 25-39, and ≥40 years, respectively) and racial/ethnicity groups (2.89, 0.47, 0.77, and 0.63 maternal deaths per 100,000 live births for Black non-Hispanics, other non-Hispanics, White non-Hispanics, and Hispanics, respectively).
CONCLUSION
Maternal mortality rates related to pulmonary embolism did not decrease during the period from 2003 to 2020, as opposed to mortality rates related to pulmonary embolism in the general population. More research is required to assess whether improvement in venous thromboembolism prevention and pulmonary embolism diagnosis and management strategies might reduce death owing to pulmonary embolism in this vulnerable population.

Identifiants

pubmed: 36155111
pii: S2589-9333(22)00185-9
doi: 10.1016/j.ajogmf.2022.100754
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

100754

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Ioannis T Farmakis (IT)

Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany (Drs Farmakis, Barco, Hobohm, Keller, Mavromanoli, Konstantinides, and Valerio).

Stefano Barco (S)

Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany (Drs Farmakis, Barco, Hobohm, Keller, Mavromanoli, Konstantinides, and Valerio); Department of Angiology, University Hospital of Zurich, Zurich, Switzerland (Dr Barco).

Lukas Hobohm (L)

Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany (Drs Farmakis, Barco, Hobohm, Keller, Mavromanoli, Konstantinides, and Valerio); Department of Cardiology, University Medical Center Mainz, Mainz, Germany (Drs Hobohm, Keller, and Valerio).

Sigrid K Braekkan (SK)

Thrombosis Research Center (TREC), Department of Clinical Medicine, University of Tromsø - The Arctic University of Norway, Tromsø, Norway (Dr Braekkan); Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway (Dr Braekkan).

Jean M Connors (JM)

Hematology Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (Dr Connors).

George Giannakoulas (G)

Department of Cardiology, AHEPA University General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece (Dr Giannakoulas).

Beverley J Hunt (BJ)

St Thomas' Hospital Thrombosis and Haemophilia Centre and Thrombosis and Vascular Biology Group, Guy's and St Thomas' National Health Service Foundation Trust, London, United Kingdom (Dr Hunt).

Karsten Keller (K)

Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany (Drs Farmakis, Barco, Hobohm, Keller, Mavromanoli, Konstantinides, and Valerio); Department of Cardiology, University Medical Center Mainz, Mainz, Germany (Drs Hobohm, Keller, and Valerio); Medical Clinic VII, Department of Sports Medicine, University Hospital Heidelberg, Heidelberg, Germany (Dr Keller).

Anna C Mavromanoli (AC)

Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany (Drs Farmakis, Barco, Hobohm, Keller, Mavromanoli, Konstantinides, and Valerio).

Alice Trinchero (A)

Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland (Dr Trinchero).

Stavros V Konstantinides (SV)

Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany (Drs Farmakis, Barco, Hobohm, Keller, Mavromanoli, Konstantinides, and Valerio); Department of Cardiology, Democritus University of Thrace, Komotini, Greece (Dr Konstantinides).

Luca Valerio (L)

Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany (Drs Farmakis, Barco, Hobohm, Keller, Mavromanoli, Konstantinides, and Valerio); Department of Cardiology, University Medical Center Mainz, Mainz, Germany (Drs Hobohm, Keller, and Valerio). Electronic address: luca.valerio@uni-mainz.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH